Labiotech.eu

News and Trends 8 Sep 2017

Spanish Scientists Identify How Gene Activity in Bacteria is Controlled

A group in Barcelona has identified DNA close to genes that influence gene activity, which could be used in disease treatment and industrial biotechnology. Sections of DNA, termed ‘control dials‘, regulate transcription, and the amount of gene product produced. Reported in Nature Communications, these findings could help to control dangerous genes during a bacterial infection […]

September 8, 2017 - 2 minutesmins - By Alex Dale

News and Trends 7 Sep 2017

Spanish Biotech Receives €4.2 Million To Continue Development of Anti-Cancer Peptide

Investment will allow Peptomyc to continue the development of their peptide cancer therapy with reduced side effects. Peptomyc gained €4.2M from a group of investors led by Alta Life Sciences at Series A of fundraising. Peptomyc is part of the growing biotech hub in Barcelona, Spain. A spin-out was formed following research carried out at […]

September 7, 2017 - 2 minutesmins - By Alex Dale

News and Trends 7 Sep 2017

Scottish Oncology Biotech Aims for €96M IPO in the Nasdaq

Nucana Biomed has filed for a Nasdaq IPO in which it expects to raise up to $115M (€96M) to support the progression of its oncology pipeline. Nucana Biomed, a biotech based in Edinburgh, specializes in using phosphoramidate chemistry to upgrade nucleoside analogs, a common form of chemotherapy drugs. With its pipeline reaching late stages of […]

September 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Sep 2017

Verona Achieves Successful Results for Phase IIa Trial of Deadly Lung Disease Drug

A study of Verona’s combination therapy for COPD observed a clinical improvement in lung function and faster onset-of-action. Verona filed for its US IPO and dosed the first patient in the trial in April, and it is now receiving initial results. This could explain a recent increase in their share price on the London Stock Exchange by […]

September 7, 2017 - 2 minutesmins - By Alex Dale

Circassia pharmaceuticals astrazeneca pulmonary disease

News and Trends 7 Sep 2017

Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success

Circassia has positive Phase III results from its respiratory pipeline, great news for the company after abandoning its allergy immunotherapies due to clinical failure. Circassia Pharmaceuticals, based in Oxford, has reported a Phase III success with Duaklir, a drug combination for the treatment of chronic obstructive pulmonary disease (COPD). The trial was run by AstraZeneca, […]

September 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Sep 2017

CAR-T is Nearly Here: How Will It Be Delivered?

As we anticipate the first-ever CAR-T therapy market approval we look at the important aspect of treatment delivery and viral vector strategies. Cell and gene therapy is increasingly coming into its own with some of the major pharma players releasing big headlines. GlaxoSmithKline (GSK) released the first ex vivo stem cell therapy in May 2016 […]

September 7, 2017 - 4 minutesmins - By External Contributor

News and Trends 6 Sep 2017

Tiziana‘s Antibody Formulation Enters Phase IIa Trial for Liver Disease Treatment

Tiziana makes moves towards a €37B market with an oral monoclonal antibody (mAb) formulation to treat non-alcoholic steatohepatitis (NASH) . Tiziana, which has previously developed compounds targeting the second most deadly form of cancer, has produced a novel formulation of the anti-CD3 mAb, Foralumab. The biologic will be tested in patients with NASH and other […]

September 6, 2017 - 3 minutesmins - By Alex Dale

News and Trends 6 Sep 2017

MSD Offers €464M to Buy German Biotech Fighting Cancer with RNA

MSD is back in the RNA field with the acquisition of Rigontec, a German biotech harnessing RNA interference to make the immune system attack cancer cells. After selling selling Sirna Therapeutics three years ago for almost a tenth of the acquisition price, it seemed like MSD was out of the RNA field. However, the big […]

September 6, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Bicycle Therapeutics Bioverativ Hemophilia blood disorders

News and Trends 6 Sep 2017

A €344M Partnership will Develop Bicycle Drugs for Hemophilia

Bicycle Therapeutics has partnered with Bioverativ to develop a new class of drugs for patients with rare blood disorders like hemophilia and sickle cell disease. Bicycle Therapeutics, a money-magnet biotech founded by Greg Winter, has closed a deal with US firm Bioverativ for the discovery, development and commercialization of bicycle drugs for rare blood disorders. […]

September 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

GARDP Antibiotic Resistance Europe Germany

News and Trends 6 Sep 2017

Europe Gives the Antibiotic Resistance Fight a Major Cash Injection

Six European countries, the UK’s Wellcome Trust and South Africa have committed €56.5M to the GARDP to work on breaking antibiotic resistance. The Global Antibiotic Research and Development Partnership (GARDP) has received this week €56.5M of funding to boost its activity, focused in promoting the development of new antibiotics. The investment comes mainly from Germany, […]

September 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Sep 2017

What to Do When the Microorganisms Get to You

For the first time ever an injectable clinical batch has been manufactured with the help of single-use technologies. A great way of fighting unwanted contamination in drug development! Have you ever opened a petri-dish and found an unknown growth on your medium? The same medium you had carefully prepared by meticulously spreading the sample over […]

September 6, 2017 - 5 minutesmins - By External Contributor

Interview 6 Sep 2017

The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue

Gilead has just splashed out $12 billion for Kite Pharma, and the FDA is currently reviewing Novartis’ Marketing Approval Application for the first-ever CAR-T therapy. I sat down with Gregg Sando of Cell Medica to hear the perspective of a biotech vying for a piece of the pie. Though he spent 20 years in investment […]

September 6, 2017 - 6 minutesmins - By Evelyn Warner

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Spanish Scientists Identify How Gene Activity in Bacteria is Controlled

Spanish Biotech Receives €4.2 Million To Continue Development of Anti-Cancer Peptide

Scottish Oncology Biotech Aims for €96M IPO in the Nasdaq

Verona Achieves Successful Results for Phase IIa Trial of Deadly Lung Disease Drug

Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success

CAR-T is Nearly Here: How Will It Be Delivered?

Tiziana‘s Antibody Formulation Enters Phase IIa Trial for Liver Disease Treatment

MSD Offers €464M to Buy German Biotech Fighting Cancer with RNA

A €344M Partnership will Develop Bicycle Drugs for Hemophilia

Europe Gives the Antibiotic Resistance Fight a Major Cash Injection

What to Do When the Microorganisms Get to You

The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!